Introduction
Crohn's disease (CD) is a regional enteritis that affects the terminal ileum, but has the potential of involving any segment of the gastrointestinal tract of the patient.
The etiology of CD is unknown, but several proven risk factors exist such as family history, smoking, oral contraceptives, diet, and ethnicity. The combination of risk factors, and aberrant autoimmune response in the intestinal mucosa with endothelial dysfunction lead to digestive tract malfunctioning. The current treatment is not ideal. Therapy generally involves steroids and antitumor necrosis factor alpha blockers but about one-third of patients fail to respond (primary nonresponders) and 10% of patients do not tolerate or are primary nonresponders to all drugs used. One-third of responders to antitumor necrosis factor treatment show transient loss of response (secondary nonresponders). Severe cases may require partial resection of a segment of bowel, possibly total colectomy with the placement of stoma bags for feces when the disease affects the rectum.
Ophthalmic manifestations have been reported to occur in up to 12% of patients with CD and most of them include iritis, uveitis, episcleritis, and conjunctivitis. However, posterior segment manifestations are very rare, occurring in less than 1% of patients.
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Case report
A 28-year-old female was admitted because of sudden decrease of visual acuity in the right eye. She had been diagnosed as suffering from CD. She had undergone resection of a 40 cm segment of bowel due to stenosis. She was refractory to treatment using 
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Ischemic retinopathy with Crohn's disease corticosteroids, azathioprine, infliximab, and adalimumab. The patient suffered repeated episodes of abdominal pain, mucous bloody diarrhea, weight loss, and depression. At presentation, she underwent a complete ophthalmological examination. Visual acuity was 20/400 in the right eye. Examination of the anterior segment was normal and the lens was clear. Bilateral intraocular pressure was 13 mmHg. Ophthalmoscopic examination with mydriasis showed severe ischemic retinopathy in the right eye ( Figure 1A ). Retinal fluorescein angiography showed ischemic retinopathy, especially involving the macular area ( Figure 1B) . Optical coherence tomography showed thickening and hyperreflectivity of the inner retinal layers, including the nerve fiber and ganglion cell layers owing to ischemia of the superficial capillary plexus ( Figure 1C ) and multifocal electroretinography showed a decrease of electrical responses representing central macula ( Figure 1D ).
These features suggested the clinical diagnosis of ischemic retinopathy secondary to CD.
We prescribed prednisone 60 mg daily and scheduled new follow-up tests.
Visual acuity showed a slight improvement (20/150), with resolution of cotton wool spots ( Figure 1E ) and reperfusion of some previously ischemic areas during examination with fluorescein ( Figure 1F) . After 3 months, we observed the formation of an epiretinal membrane ( Figure 1G ), but without significant macular edema or bleeding. Multifocal electroretinography remained at low amplitudes meaning macular dysfunction ( Figure 1H ).
Discussion
We present a case of CD complicated by ischemic retinopathy with irreversible damage of central visual acuity.
Several factors are associated with an increased risk of ocular manifestations. Patients with colitis and ileocolitis tend to have a higher risk of ocular involvement compared to those with ileitis alone. 5 Presence of other organ involvement also increases the risk. 5, 6 Particularly, in patients with CD and arthralgia, the risk of ocular involvement increases to 33%. 6 Falavarjani et al 7 described a 9-year-old male with biopsyproven CD who developed a cilioretinal artery-sparing central retinal artery occlusion. Trojet et al 8 reported a 55-year-old male with CD with associated retinal vasculitis involving the veins, papillitis, cystoid macular edema.
The pathophysiology of the extraintestinal manifestations of CD is not well understood, but it is most likely mediated by the inflammatory nature of the disease. Several proposed mechanisms include circulating antigen-antibody complexes or autoantibody production against cellular antigens shared by the colon and extraintestinal organs. 9 Inflammation causing damage to mucosa of the intestinal epithelium may allow proteins or microorganisms to pass through the intestinal barrier and cause a reactive lymphoid tissue response. This, in turn, results in antibody production or antigen-antibody complexes that circulate in the body and cause systemic inflammation. This immune response to a colonic antigen may explain why ocular manifestations may occur more commonly with colitis and ileocolitis than with small bowel involvement alone. Microbial pathogens, through molecular mimicry, may also contribute to the pathogenesis, though this is still being investigated. Genetic factors may also play a role in ocular manifestations. Patients with extraintestinal manifestations of CD have a higher prevalence of HLA-B27 type leukocytes than the regular. 10 Ocular complications are categorized as primary, secondary, and coincidental. 11 Primary complications are temporally associated with CD exacerbations and tend to resolve with systemic treatment of the intestinal inflammation. These include keratopathy, episcleritis, and scleritis. Secondary complications arise from primary complications. Examples include cataract formation due to treatment with corticosteroids, scleromalacia due to scleritis, and dry eye due to hypovitaminosis A following gut resection. Coincidental complications occur commonly in the general population and cannot be correlated to inflammatory bowel disease alone. These include conjunctivitis, recurrent corneal erosions, and corneal ulcer.
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Ocular involvement does not always coincide with active intestinal flare. However, in instances when it does, as is typical of episcleritis, this can be used as an indicator of disease activity, indicating the need for more aggressive management. 12 In this case report, the pathogenesis of ischemia in retinal vasculitis is not clear but is suggested to be either thrombotic or obliterative, secondary to the infiltration of inflammatory cells. Based on histological studies, vascular changes in uveitis are characterized by perivascular infiltration of lymphocytes, which results in perivasculitis rather than true vasculitis of the vessel wall.
14 Cell-mediated immunity also plays a role in the pathology of retinal vasculitis, with CD4+ T cells documented within and around the retinal vessels. Thrombotic vascular changes can occur due to local endothelial injury or increased prothrombin activity as observed in Behçet's disease. 14, 15 The retina has a uniquely high metabolic demand for oxygen that is normally met by a highly efficient vascular supply. The International Medical Case Reports Journal is an international, peer-reviewed open-access journal publishing original case reports from all medical specialties. Previously unpublished medical posters are also accepted relating to any area of clinical or preclinical science. Submissions should not normally exceed 2,000 words or 4 published pages including figures, diagrams and references. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
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Siqueira et al circulation causes neuroretinal dysfunction and degeneration. Focal retinal ischemia results in selective damage to specific subpopulations of retinal neurons and can result in cellular death by apoptosis or necrosis, with dysfunction and degeneration of the inner retina and eventually visual loss. Retinal vascular obstruction can also promote the production of vascular endothelial growth factor, which increases vascular permeability and results in macular edema and induced neovascularization. 15, 16 Treatment of ocular manifestations ranges from controlling the underlying intestinal inflammation, topical steroids, systemic nonsteroidal anti-inflammatory drugs, systemic steroids, and immunosuppressant and biological agents. In refractory or severe cases, treatment with monoclonal antibodies has shown promise.
Periodic examination by a retina specialist is recommended for patients being treated for CD.
